Curriculum Vitae

Name: Kazuaki Chayama

Current Position:

Professor, Department of Gastroenterology and Metabolism,
Applied Life Sciences, Graduate School of Biomedical & Health Sciences,
Hiroshima University

Education:

1981: Graduated from Hiroshima University

1981: Medical Doctor's license in Japan

1997: PhD in Medical Science from Tokyo University for a thesis entitled "Nucleotide sequence and genome organization of a rare hepatitis C virus genotype (genotype 3b) isolated from a Japanese patient with chronic hepatitis C."

Occupation:

1981: Doctor, Department of Internal Medicine, Mimihara General Hospital

1986: Doctor, Department of Internal Medicine, Toranomon Hospital

1996: Head Physician, Department of Internal Medicine, Toranomon Hospital

2000: Professor of Medicine, Faculty of Medicine, Hiroshima University

2002–present: Professor, Department of Gastroenterology and Metabolism, Applied Life Sciences, Graduate School of Biomedical & Health Sciences, Hiroshima University

2011, April - 2015, March: Director of Hiroshima University Hospital

2012, April - 2015, March: Executive and Vice President, Hiroshima University

2015, April - 2016, March: Special Assistant to the President

Specialty fields: Gastroenterology, Viral Hepatitis

Awards: 16th Oda Award of Japan Society of Hepatology (2012)

Affiliated societies:

The Japanese Society of Gastroenterology

The Japanese Society of Internal Medicine

Japan Gastroenterological Endoscopy Society
Japanese Society for Immunology
Japanese Cancer Association
The Japan Society of Hepatology
Japan Diabetes Society
The Japanese Society for Virology
Japan Society of Clinical Oncology
The Molecular Biology Society of Japan
American Association for the Study of Liver Diseases
Asia Pacific Association for the study of the Liver
European Association for the study of the Liver

Major published papers (23 of 1017 publications):

1. Van Renne N, Roca Suarez AA, **Chayama K**. et al. miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis. ***Gut***. 2017; in press.
2. Fujimoto A, Furuta M, **Chayama K**. et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. ***Nat Genet***. 2016; 48: 500-509.
3. Aizawa S, Okamoto T, **Chayama K**. et al. TRC8-dependent degradation of hepatitis C virus immature core protein regulates viral propagation and pathogenesis. ***Nat Commun***. 2016; 7: 11379.
4. He S, Lin B, **Chayama K**. et al. Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. ***Sci Transl Med***. 2015; 7: 282ra249.
5. Fujimoto A, Furuta M, **Chayama K**. et al. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity. ***Nat Commun***. 2015; 6: 6120.
6. Abe Y, Aly HH, , **Chayama K**. et al. Thromboxane A2 synthase inhibitors prevent production of infectious hepatitis C virus in mice with humanized livers. ***Gastroenterology***. 2013; 145: 658-667: e611.
7. Shi N, Hiraga N, **Chayama K**. et al. Combination therapies with NS5A, NS3 and NS5B

inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice. ***Gut***. 2013; 62: 1055-1061.

8. Fujimoto A, Totoki Y, **Chayama K**. et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. ***Nat Genet***. 2012; 44: 760-764.
9. Sainz B, Barretto N, **Chayama K**. et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. ***Nat Med***. 2012; 18: 281-285.
10. Hayes CN, Imamura M, **Chayama K**. et al. Genetics of IL28B and HCV--response to infection and treatment. ***Nat Rev Gastroenterol Hepatol***. 2012; 9: 406-417.
11. Miki D, Ochi H, **Chayama K**. et al. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. ***Nat Genet***. 2011; 43: 797-800.
12. Wakita T, Suzuki T, **Chayama K**. et al. Will there be an HCV meeting in 2020? Summary of the 17th international meeting on hepatitis C virus and related viruses. ***Gastroenterology***. 2011; 141: e1-5.
13. Hayes CN, Kobayashi M, **Chayama K**. et al. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. ***Gut***. 2011; 60: 261-267.
14. Miki D, Kubo M, **Chayama K**. et al. Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations. ***Nat Genet***. 2010; 42: 893-896.
15. Ochi H, Maekawa T, **Chayama K**. et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients. ***Gastroenterology***. 2010; 139: 1190-1197.
16. Kamatani Y, Wattanapokayakit S, **Chayama K**, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. ***Nat Genet***. 2009; 41: 591-595.
17. Matsumura T, Hu Z, **Chayama K**, et al. Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. ***Gastroenterology***. 2009; 137: 673-681.
18. Tsukada H, Ochi H, **Chayama K**. et al. A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C. ***Gastroenterology***. 2009; 136: 1796-1805 e1796.
19. Ohira M, Ishiyama K, **Chayama K**. et al. Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and

humanized mice. ***J Clin Invest***. 2009; 119: 3226-3235.

20. Soetikno R, Friedland S, **Chayama K**. et al. Nonpolypoid (flat and depressed) colorectal neoplasms. ***Gastroenterology***. 2006 130 566-576; quiz 588-569.
21. Tsuge M, Hamamoto R, **Chayama K**. et al. A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers. ***Nat Genet***. 2005; 37: 1104-1107.
22. Imamura M, Ogawa T, **Chayama K**. et al. Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. ***Gastroenterology***. 2005; 128: 138-146.
23. Higashi Y, Sasaki S, **Chayama K**. et al. Endothelial function and oxidative stress in renovascular hypertension. ***N Engl J Med***. 2002; 346: 1954-1962.